An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Act ...
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In) A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seaml ...